Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
life sciences
national blog main
new york blog main
8
×
boston blog main
boston top stories
indiana blog main
national top stories
new york top stories
san diego blog main
san francisco blog main
clinical trials
indiana top stories
raleigh-durham blog main
san diego top stories
san francisco top stories
seattle blog main
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
fda
national
raleigh-durham top stories
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
boston
deals
medicare
merck
novartis
pfizer
type 1 diabetes
venture capital
alnylam pharmaceuticals
What
patients
8
×
drug
bio
fda
market
medicine
roundup
diabetes
type
acquisitions
advantages
ago
albert
alnylam
approval
approve
awaits
bar
becker
benefiting
beta
bid
biggest
billions
biological
bionics
blood
boehringer
boston
bourla
brings
cancer
ceo
closed
coming
company
crispr
crossed
decades
decision
Language
unset
unknown
Current search:
biotech
×
" new york blog main "
×
patients
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision